Impact of spliceosome mutations on RNA splicing in myelodysplasia: Dysregulated genes/pathways and clinical associations

Andrea Pellagatti, Richard N. Armstrong, Violetta Steeples, Eshita Sharma, Emmanouela Repapi, Shalini Singh, Andrea Sanchi, Aleksandar Radujkovic, Patrick Horn, Hamid Dolatshad, Swagata Roy, John Broxholme, Helen Lockstone, Stephen Taylor, Aristoteles Giagounidis, Paresh Vyas, Anna Schuh, Angela Hamblin, Elli Papaemmanuil, Sally KillickLuca Malcovati, Marco L. Hennrich, Anne Claude Gavin, Anthony D. Ho, Thomas Luft, Eva Hellström-Lindberg, Mario Cazzola, Christopher W.J. Smith, Stephen Smith, Jacqueline Boultwood

Research output: Contribution to journalArticle

Abstract

SF3B1, SRSF2, and U2AF1 are the most frequently mutated splicing factor genes in the myelodysplastic syndromes (MDS). We have performed a comprehensive and systematic analysis to determine the effect of these commonly mutated splicing factors on pre-mRNA splicing in the bone marrow stem/progenitor cells and in the erythroid and myeloid precursors in splicing factor mutant MDS. Using RNA-seq, we determined the aberrantly spliced genes and dysregulated pathways in CD34+ cells of 84 patients with MDS. Splicing factor mutations result in different alterations in splicing and largely affect different genes, but these converge in common dysregulated pathways and cellular processes, focused on RNA splicing, protein synthesis, and mitochondrial dysfunction, suggesting common mechanisms of action in MDS. Many of these dysregulated pathways and cellular processes can be linked to the known disease pathophysiology associated with splicing factor mutations in MDS, whereas several others have not been previously associated with MDS, such as sirtuin signaling. We identified aberrantly spliced events associated with clinical variables, and isoforms that independently predict survival in MDS and implicate dysregulation of focal adhesion and extracellular exosomes as drivers of poor survival. Aberrantly spliced genes and dysregulated pathways were identified in the MDS-affected lineages in splicing factor mutant MDS. Functional studies demonstrated that knockdown of the mitosis regulators SEPT2 and AKAP8, aberrantly spliced target genes of SF3B1 and SRSF2 mutations, respectively, led to impaired erythroid cell growth and differentiation. This study illuminates the effect of the common spliceosome mutations on the MDS phenotype and provides novel insights into disease pathophysiology.

Original languageEnglish
Pages (from-to)1225-1240
Number of pages16
JournalBlood
Volume132
Issue number12
DOIs
Publication statusPublished - Sep 20 2018

Fingerprint

Spliceosomes
RNA Splicing
Critical Pathways
Myelodysplastic Syndromes
Recombinant DNA
Genes
RNA
Mutation
RNA Precursors
Cell growth
Stem cells
Protein Isoforms
Bone
Adhesion
Cells
Stem Cells
Exosomes
Proteins
Erythroid Cells
Focal Adhesions

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Pellagatti, A., Armstrong, R. N., Steeples, V., Sharma, E., Repapi, E., Singh, S., ... Boultwood, J. (2018). Impact of spliceosome mutations on RNA splicing in myelodysplasia: Dysregulated genes/pathways and clinical associations. Blood, 132(12), 1225-1240. https://doi.org/10.1182/blood-2018-04-843771

Impact of spliceosome mutations on RNA splicing in myelodysplasia : Dysregulated genes/pathways and clinical associations. / Pellagatti, Andrea; Armstrong, Richard N.; Steeples, Violetta; Sharma, Eshita; Repapi, Emmanouela; Singh, Shalini; Sanchi, Andrea; Radujkovic, Aleksandar; Horn, Patrick; Dolatshad, Hamid; Roy, Swagata; Broxholme, John; Lockstone, Helen; Taylor, Stephen; Giagounidis, Aristoteles; Vyas, Paresh; Schuh, Anna; Hamblin, Angela; Papaemmanuil, Elli; Killick, Sally; Malcovati, Luca; Hennrich, Marco L.; Gavin, Anne Claude; Ho, Anthony D.; Luft, Thomas; Hellström-Lindberg, Eva; Cazzola, Mario; Smith, Christopher W.J.; Smith, Stephen; Boultwood, Jacqueline.

In: Blood, Vol. 132, No. 12, 20.09.2018, p. 1225-1240.

Research output: Contribution to journalArticle

Pellagatti, A, Armstrong, RN, Steeples, V, Sharma, E, Repapi, E, Singh, S, Sanchi, A, Radujkovic, A, Horn, P, Dolatshad, H, Roy, S, Broxholme, J, Lockstone, H, Taylor, S, Giagounidis, A, Vyas, P, Schuh, A, Hamblin, A, Papaemmanuil, E, Killick, S, Malcovati, L, Hennrich, ML, Gavin, AC, Ho, AD, Luft, T, Hellström-Lindberg, E, Cazzola, M, Smith, CWJ, Smith, S & Boultwood, J 2018, 'Impact of spliceosome mutations on RNA splicing in myelodysplasia: Dysregulated genes/pathways and clinical associations', Blood, vol. 132, no. 12, pp. 1225-1240. https://doi.org/10.1182/blood-2018-04-843771
Pellagatti, Andrea ; Armstrong, Richard N. ; Steeples, Violetta ; Sharma, Eshita ; Repapi, Emmanouela ; Singh, Shalini ; Sanchi, Andrea ; Radujkovic, Aleksandar ; Horn, Patrick ; Dolatshad, Hamid ; Roy, Swagata ; Broxholme, John ; Lockstone, Helen ; Taylor, Stephen ; Giagounidis, Aristoteles ; Vyas, Paresh ; Schuh, Anna ; Hamblin, Angela ; Papaemmanuil, Elli ; Killick, Sally ; Malcovati, Luca ; Hennrich, Marco L. ; Gavin, Anne Claude ; Ho, Anthony D. ; Luft, Thomas ; Hellström-Lindberg, Eva ; Cazzola, Mario ; Smith, Christopher W.J. ; Smith, Stephen ; Boultwood, Jacqueline. / Impact of spliceosome mutations on RNA splicing in myelodysplasia : Dysregulated genes/pathways and clinical associations. In: Blood. 2018 ; Vol. 132, No. 12. pp. 1225-1240.
@article{918999e3754a414490e2b3b3c9f6c48b,
title = "Impact of spliceosome mutations on RNA splicing in myelodysplasia: Dysregulated genes/pathways and clinical associations",
abstract = "SF3B1, SRSF2, and U2AF1 are the most frequently mutated splicing factor genes in the myelodysplastic syndromes (MDS). We have performed a comprehensive and systematic analysis to determine the effect of these commonly mutated splicing factors on pre-mRNA splicing in the bone marrow stem/progenitor cells and in the erythroid and myeloid precursors in splicing factor mutant MDS. Using RNA-seq, we determined the aberrantly spliced genes and dysregulated pathways in CD34+ cells of 84 patients with MDS. Splicing factor mutations result in different alterations in splicing and largely affect different genes, but these converge in common dysregulated pathways and cellular processes, focused on RNA splicing, protein synthesis, and mitochondrial dysfunction, suggesting common mechanisms of action in MDS. Many of these dysregulated pathways and cellular processes can be linked to the known disease pathophysiology associated with splicing factor mutations in MDS, whereas several others have not been previously associated with MDS, such as sirtuin signaling. We identified aberrantly spliced events associated with clinical variables, and isoforms that independently predict survival in MDS and implicate dysregulation of focal adhesion and extracellular exosomes as drivers of poor survival. Aberrantly spliced genes and dysregulated pathways were identified in the MDS-affected lineages in splicing factor mutant MDS. Functional studies demonstrated that knockdown of the mitosis regulators SEPT2 and AKAP8, aberrantly spliced target genes of SF3B1 and SRSF2 mutations, respectively, led to impaired erythroid cell growth and differentiation. This study illuminates the effect of the common spliceosome mutations on the MDS phenotype and provides novel insights into disease pathophysiology.",
author = "Andrea Pellagatti and Armstrong, {Richard N.} and Violetta Steeples and Eshita Sharma and Emmanouela Repapi and Shalini Singh and Andrea Sanchi and Aleksandar Radujkovic and Patrick Horn and Hamid Dolatshad and Swagata Roy and John Broxholme and Helen Lockstone and Stephen Taylor and Aristoteles Giagounidis and Paresh Vyas and Anna Schuh and Angela Hamblin and Elli Papaemmanuil and Sally Killick and Luca Malcovati and Hennrich, {Marco L.} and Gavin, {Anne Claude} and Ho, {Anthony D.} and Thomas Luft and Eva Hellstr{\"o}m-Lindberg and Mario Cazzola and Smith, {Christopher W.J.} and Stephen Smith and Jacqueline Boultwood",
year = "2018",
month = "9",
day = "20",
doi = "10.1182/blood-2018-04-843771",
language = "English",
volume = "132",
pages = "1225--1240",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Impact of spliceosome mutations on RNA splicing in myelodysplasia

T2 - Dysregulated genes/pathways and clinical associations

AU - Pellagatti, Andrea

AU - Armstrong, Richard N.

AU - Steeples, Violetta

AU - Sharma, Eshita

AU - Repapi, Emmanouela

AU - Singh, Shalini

AU - Sanchi, Andrea

AU - Radujkovic, Aleksandar

AU - Horn, Patrick

AU - Dolatshad, Hamid

AU - Roy, Swagata

AU - Broxholme, John

AU - Lockstone, Helen

AU - Taylor, Stephen

AU - Giagounidis, Aristoteles

AU - Vyas, Paresh

AU - Schuh, Anna

AU - Hamblin, Angela

AU - Papaemmanuil, Elli

AU - Killick, Sally

AU - Malcovati, Luca

AU - Hennrich, Marco L.

AU - Gavin, Anne Claude

AU - Ho, Anthony D.

AU - Luft, Thomas

AU - Hellström-Lindberg, Eva

AU - Cazzola, Mario

AU - Smith, Christopher W.J.

AU - Smith, Stephen

AU - Boultwood, Jacqueline

PY - 2018/9/20

Y1 - 2018/9/20

N2 - SF3B1, SRSF2, and U2AF1 are the most frequently mutated splicing factor genes in the myelodysplastic syndromes (MDS). We have performed a comprehensive and systematic analysis to determine the effect of these commonly mutated splicing factors on pre-mRNA splicing in the bone marrow stem/progenitor cells and in the erythroid and myeloid precursors in splicing factor mutant MDS. Using RNA-seq, we determined the aberrantly spliced genes and dysregulated pathways in CD34+ cells of 84 patients with MDS. Splicing factor mutations result in different alterations in splicing and largely affect different genes, but these converge in common dysregulated pathways and cellular processes, focused on RNA splicing, protein synthesis, and mitochondrial dysfunction, suggesting common mechanisms of action in MDS. Many of these dysregulated pathways and cellular processes can be linked to the known disease pathophysiology associated with splicing factor mutations in MDS, whereas several others have not been previously associated with MDS, such as sirtuin signaling. We identified aberrantly spliced events associated with clinical variables, and isoforms that independently predict survival in MDS and implicate dysregulation of focal adhesion and extracellular exosomes as drivers of poor survival. Aberrantly spliced genes and dysregulated pathways were identified in the MDS-affected lineages in splicing factor mutant MDS. Functional studies demonstrated that knockdown of the mitosis regulators SEPT2 and AKAP8, aberrantly spliced target genes of SF3B1 and SRSF2 mutations, respectively, led to impaired erythroid cell growth and differentiation. This study illuminates the effect of the common spliceosome mutations on the MDS phenotype and provides novel insights into disease pathophysiology.

AB - SF3B1, SRSF2, and U2AF1 are the most frequently mutated splicing factor genes in the myelodysplastic syndromes (MDS). We have performed a comprehensive and systematic analysis to determine the effect of these commonly mutated splicing factors on pre-mRNA splicing in the bone marrow stem/progenitor cells and in the erythroid and myeloid precursors in splicing factor mutant MDS. Using RNA-seq, we determined the aberrantly spliced genes and dysregulated pathways in CD34+ cells of 84 patients with MDS. Splicing factor mutations result in different alterations in splicing and largely affect different genes, but these converge in common dysregulated pathways and cellular processes, focused on RNA splicing, protein synthesis, and mitochondrial dysfunction, suggesting common mechanisms of action in MDS. Many of these dysregulated pathways and cellular processes can be linked to the known disease pathophysiology associated with splicing factor mutations in MDS, whereas several others have not been previously associated with MDS, such as sirtuin signaling. We identified aberrantly spliced events associated with clinical variables, and isoforms that independently predict survival in MDS and implicate dysregulation of focal adhesion and extracellular exosomes as drivers of poor survival. Aberrantly spliced genes and dysregulated pathways were identified in the MDS-affected lineages in splicing factor mutant MDS. Functional studies demonstrated that knockdown of the mitosis regulators SEPT2 and AKAP8, aberrantly spliced target genes of SF3B1 and SRSF2 mutations, respectively, led to impaired erythroid cell growth and differentiation. This study illuminates the effect of the common spliceosome mutations on the MDS phenotype and provides novel insights into disease pathophysiology.

UR - http://www.scopus.com/inward/record.url?scp=85054005808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054005808&partnerID=8YFLogxK

U2 - 10.1182/blood-2018-04-843771

DO - 10.1182/blood-2018-04-843771

M3 - Article

AN - SCOPUS:85054005808

VL - 132

SP - 1225

EP - 1240

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -